Cilcare Secures Funding to Advance Clinical Trials for Cochlear Synaptopathy Treatment
Cilcare raised €40 million in Series A funding to initiate two clinical trials in 2025 for treatment of cochlear synaptopathy.
Cilcare raised €40 million in Series A funding to initiate two clinical trials in 2025 for treatment of cochlear synaptopathy.
A national poll by ASHA reveals that a majority of adults with communication disorders experience significant stigmas.
When a COVID-19 survivor reports that they have been diagnosed with brain fog or mild cognitive impairment (BF/MCI), or these terms appear in a medical report, hearing care professionals should be aware that many of the BF/MCI symptoms are very similar to those seen in patients with (central) auditory processing disorder. This article by audiologist Robert DiSogra, AuD, reviews the research on this subject and provides recommendations.
Merri Rosen, PhD, director of Hearing Research at Northeast Ohio Medical University, has been...
In an article published on the ”Discover Magazine” website, author Sarah Katz challenges the view in the scientific community that deafness is a problem that needs to be cured, potentially by new CRISPR technology that could eliminate a TMC1 gene mutation.
The researchers concluded that “SARS‐CoV‐2 is a probable cause of middle ear infections and sensorineural hearing loss, secondary to spread of the novel virus into the middle ear and related neural structures.”
ClearDrum is a “world-first, acoustically optimized” silk fibroin implant for the treatment of chronic middle ear disease (CMED).